FURTHER ANALYSIS OF THE USE OF TOXOPLASMA GONDII SERINE PROTEASAE INHIBITOR-1 FOR THE TREATMENT OF ALLERGIC LUNG INFLAMMATION

SOTO ARIADNA; FENOY IGNACIO; SÁNCHEZ VANESA ROXANA; MARCH FLORENCIA; PICCHIO MARIANO; PERRONE MATIAS; ALDIRICO MARÍA DE LOS ANGELES; DRAN GRACIELA; VALENTINA MARTIN; ALEJANDRA GOLDMAN

Congreso; LXII REUNIÓN ANUAL Sociedad Argentina de Inmunología; 2014

By using a murine allergic airway inflammation model, we had previously shown that Toxoplasma gondii serin-proteases inhibitor 1 (PI) was able to reduce BAL eosinophilia and lung mucus production. Herein, we extended our study by analysing the immune mechanisms involved. BALB/c mice were ip sensitized with OVA (allergen) /Alum and aerosol challenged with OVA. Two days later they were intranasally (IN) treated for 3 days with OVA + PI (OPI). Control groups included non-sensitized mice IN treated with PI alone (NPI) (negative) and sensitized mice treated with OVA alone (OO) (positive). One week later, mice were OVA aerosol challenged. PI treated mice showed a decrease in OVA specific IgG1 and IgG2a (IgG1: NPIª: 0,01±0,002; OOb: 0,13±0,01; OPIc: 0,09±0,01; OD±ES p